Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR, Axitinib, and Toripalimab in Recurrent or Metastatic RCC
NCT06889649Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2019
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in renal cell carcinoma (RCC), sponsored by Peking University First Hospital. Started Jan 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06889649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889649.